These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19001511)

  • 1. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
    Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
    J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
    Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
    Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
    Kukla U; Łabuzek K; Chronowska J; Bobrzyk M; Madej P; Okopień B
    Pol Merkur Lekarski; 2015 Apr; 38(226):191-5. PubMed ID: 25938384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
    Sun FK; He HC; Su TW; Zhou WL; Huang X; Dai J; Shen ZJ
    Chin Med J (Engl); 2012 Jun; 125(12):2231-4. PubMed ID: 22884159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
    O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
    Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.
    Makis W; McCann K; McEwan AJ; Sawyer MB
    Clin Nucl Med; 2016 Mar; 41(3):204-6. PubMed ID: 26359568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib for refractory malignant pheochromocytoma: two case reports.
    Hata J; Haga N; Ishibashi K; Takahashi N; Ogawa S; Kataoka M; Akaihata H; Satoh Y; Koguchi T; Kojima Y
    Int Urol Nephrol; 2014 Jul; 46(7):1309-12. PubMed ID: 24510251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.
    Park KS; Lee JL; Ahn H; Koh JM; Park I; Choi JS; Kim YR; Park TS; Ahn JH; Lee DH; Kim TW; Lee JS
    Jpn J Clin Oncol; 2009 May; 39(5):327-31. PubMed ID: 19264767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
    Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
    Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
    Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
    Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
    Nasca V; Prinzi N; Coppa J; Prisciandaro M; Oldani S; Ghelardi F; Conca E; Capone I; Busico A; Perrone F; Tamborini E; Sabella G; Greco G; Greco FG; Tafuto S; Procopio G; Morano F; Niger M; Maccauro M; Milione M; de Braud F; Pietrantonio F; Pusceddu S
    Eur J Cancer; 2024 Sep; 209():114276. PubMed ID: 39128186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature.
    Canu L; Pradella S; Rapizzi E; Fucci R; Valeri A; Briganti V; Giachè V; Parenti G; Ercolino T; Mannelli M
    Arch Endocrinol Metab; 2017; 61(1):90-97. PubMed ID: 27737332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA flow cytometry in pheochromocytoma and paraganglioma.
    Jung WH; Yang WI; Park C; Choi IJ
    Yonsei Med J; 1992 Sep; 33(3):249-57. PubMed ID: 1292249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic paraganglioma and treatment with sunitinib: a case report.
    Cirillo F
    Tumori; 2010; 96(6):1022-7. PubMed ID: 21388069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
    Benn DE; Gimenez-Roqueplo AP; Reilly JR; Bertherat J; Burgess J; Byth K; Croxson M; Dahia PL; Elston M; Gimm O; Henley D; Herman P; Murday V; Niccoli-Sire P; Pasieka JL; Rohmer V; Tucker K; Jeunemaitre X; Marsh DJ; Plouin PF; Robinson BG
    J Clin Endocrinol Metab; 2006 Mar; 91(3):827-36. PubMed ID: 16317055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted molecular medicine: advances in the treatment of metastatic phaeochromocytoma and paraganglioma.
    Naruse M; Young WF
    Lancet; 2024 Mar; 403(10431):1001-1003. PubMed ID: 38402884
    [No Abstract]   [Full Text] [Related]  

  • 19. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center.
    Pham TH; Moir C; Thompson GB; Zarroug AE; Hamner CE; Farley D; van Heerden J; Lteif AN; Young WF
    Pediatrics; 2006 Sep; 118(3):1109-17. PubMed ID: 16951005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.